{"id":{"repo_id":"mcmaster","oai_identifier":"oai:macsphere.mcmaster.ca:11375/33591"},"canonical_url":"https://search.ndltd.org/etd/mcmaster/oai:macsphere.mcmaster.ca:11375/33591","repository":{"repo_id":"mcmaster","name":"McMaster University","base_url":"https://macsphere.mcmaster.ca/server/oai/request"},"display":{"title":"Identification and Characterization of Novel Oncogenic Factors and Predictive Biomarkers of Clear Cell Renal Cell Carcinoma","abstract":"Renal cell carcinoma (RCC) is the predominant cause of kidney cancer death, owing to the disease’s aggressiveness-associated poor prognosis as well as challenges in early diagnosis and in predicting RCC evolution path, particularly in response to therapy. Currently, RCC cases are diagnosed incidentally through imaging; the disease prognosis is evaluated based on tumors’ histological features; and immune checkpoint inhibitor (ICI) is promising in treating patients with advanced RCC by taking advantage of enriched infiltration of CD8+ T cells without reliable criteria (biomarkers) for optimizing ICI therapy. My research focuses on advancing the current understanding of RCC particularly factors relevant to RCC’s immune escape and identifying novel and effective biomarkers to improve patient management. Specifically, we investigated novel factors: Contactin 1 (CNTN1) and CYTH4 for their contributions to RCC progression, and multigene panels, Sig27 and SigRZ, as novel predictive biomarkers of RCC. Notably, CNTN1, CYTH4, and Sig27 display intrinsic connections with the immunosuppressive microenvironment of RCC. Contactin 1 (CNTN1) is a cell adhesion protein and has been reported to be associated with tumor invasion, metastasis, and poor prognosis across multiple cancer types. In this study, we demonstrate that CNTN1 expression is strongly associated with tumor aggressiveness and adverse clinical outcomes in RCC. Tumors with high expression of CNTN1 show upregulation of genes and pathways involved in cell proliferation, migration, and extracellular matrix remodeling, consistent with a highly invasive tumor state, and elevated CNTN1 expression correlates with enrichment of immunosuppressive signaling pathways and immune cell populations. In vitro, CNTN1 promotes tumor cell migration and invasion. In vivo, CNTN1-overexpressing Renca (Renca-CNTN1) allograft exhibits a biphasic growth, an early growth suppression followed by later acceleration compared to Renca-EV (empty vector) allografts. Surgical resection of early tumors (100 mm3) showed CNTN1 tumors recur at lower rates (3/10=30%) than EV allografts (10/10=100%), indicating that Renca-CNTN1 allografts initiate anti-tumor immunity which suppresses early tumor growth and their subsequent recurrence following surgical resection. Tumor cells isolated from recurrent Renca-CNTN1 tumors produced aggressive allografts in BALB/c mice compared to tumor cells isolated from Renca-EV recurrent tumors. Renca-CNTN1 tumors that escape this immunosurveillance window develop interferon-dominated transcriptional programs with co-expression of the exhaustion markers TOX, PD-1, and LAG-3, alongside CD8+ T cell infiltration with impaired cytolytic function. CNTN1 thus drives a stage-dependent immune evasion program in RCC, coupled with enhancing proliferation and the relevant pathways. CYTH4 (Cytohesin 4), a regulator of ARF-mediated signaling and cytoskeletal dynamics, was selectively enriched in immune cell subsets exhibiting altered migratory and suppressive properties. Dysregulation of CYTH4 was associated with tumor initiation and progression, highlighting its contribution to immune cell trafficking and functional reprogramming within the tumor microenvironment (TME). CYTH4 (Cytohesin-4) was identified as a novel oncogenic factor in ccRCC, with expression upregulated in tumor, lymph node metastasis, and the aggressive ccB subtype. In vitro, overexpression of CYTH4 in 786-O cells enhanced colony formation and produced more aggressive xenografts in NOD/SCID mice. Mechanistically, CYTH4 physically interacted with PPP1R9B to induce pRb hyperphosphorylation. RNA-seq of CYTH4 xenografts showed enrichment of MYC Targets and E2F Targets alongside upregulation of the Sig27 metagene, with three Sig27 component genes confirmed as CYTH4- associated differentially expressed genes (DEGs). A derived 13-gene panel SigCYTH4NW robustly stratified poor overall survival across four ccRCC cohorts and 21 cancer types with stable hazard ratios strongly correlated with an immune checkpoint panel (SigIC), and showed predominant expression in tumor-associated macrophages (TAMs), exhausted CD8+ T cells, and Tregs in single-cell datasets. We validated a prostate cancer-derived and IQGAP1 associated novel 27-gene prognostic signature (Sig27) that robustly predicts poor prognosis in RCC. Sig27 presented a strong association with immunosuppressive features of the TME, including myeloid infiltration and immune inhibitory signaling. To further explore the clinical relevance of this, we constructed SigRZ, a 2-gene signature for predicting overall survival and disease progression in advanced RCC patients treated with the PD-1 inhibitor nivolumab. SigRZ effectively stratified patients by clinical outcome, underscoring the relevance of immune-associated transcriptional programs in determining immunotherapy response. Collectively, we identified two factors as promoters of tumor aggressiveness and tumor microenvironment changes. The development or validation of Sig27 and SigRZ demonstrates the translational potential of integrating tumor-intrinsic and immuneassociated molecular programs into clinically actionable biomarkers. Taken together, the findings advance our understanding of immune-driven tumor progression and provide a conceptual framework for biomarker development for RCC progression.","abstract_html":"Renal cell carcinoma (RCC) is the predominant cause of kidney cancer death, owing to the disease’s aggressiveness-associated poor prognosis as well as challenges in early diagnosis and in predicting RCC evolution path, particularly in response to therapy. Currently, RCC cases are diagnosed incidentally through imaging; the disease prognosis is evaluated based on tumors’ histological features; and immune checkpoint inhibitor (ICI) is promising in treating patients with advanced RCC by taking advantage of enriched infiltration of CD8+ T cells without reliable criteria (biomarkers) for optimizing ICI therapy. My research focuses on advancing the current understanding of RCC particularly factors relevant to RCC’s immune escape and identifying novel and effective biomarkers to improve patient management. Specifically, we investigated novel factors: Contactin 1 (CNTN1) and CYTH4 for their contributions to RCC progression, and multigene panels, Sig27 and SigRZ, as novel predictive biomarkers of RCC. Notably, CNTN1, CYTH4, and Sig27 display intrinsic connections with the immunosuppressive microenvironment of RCC. Contactin 1 (CNTN1) is a cell adhesion protein and has been reported to be associated with tumor invasion, metastasis, and poor prognosis across multiple cancer types. In this study, we demonstrate that CNTN1 expression is strongly associated with tumor aggressiveness and adverse clinical outcomes in RCC. Tumors with high expression of CNTN1 show upregulation of genes and pathways involved in cell proliferation, migration, and extracellular matrix remodeling, consistent with a highly invasive tumor state, and elevated CNTN1 expression correlates with enrichment of immunosuppressive signaling pathways and immune cell populations. In vitro, CNTN1 promotes tumor cell migration and invasion. In vivo, CNTN1-overexpressing Renca (Renca-CNTN1) allograft exhibits a biphasic growth, an early growth suppression followed by later acceleration compared to Renca-EV (empty vector) allografts. Surgical resection of early tumors (100 mm3) showed CNTN1 tumors recur at lower rates (3/10=30%) than EV allografts (10/10=100%), indicating that Renca-CNTN1 allografts initiate anti-tumor immunity which suppresses early tumor growth and their subsequent recurrence following surgical resection. Tumor cells isolated from recurrent Renca-CNTN1 tumors produced aggressive allografts in BALB/c mice compared to tumor cells isolated from Renca-EV recurrent tumors. Renca-CNTN1 tumors that escape this immunosurveillance window develop interferon-dominated transcriptional programs with co-expression of the exhaustion markers TOX, PD-1, and LAG-3, alongside CD8+ T cell infiltration with impaired cytolytic function. CNTN1 thus drives a stage-dependent immune evasion program in RCC, coupled with enhancing proliferation and the relevant pathways. CYTH4 (Cytohesin 4), a regulator of ARF-mediated signaling and cytoskeletal dynamics, was selectively enriched in immune cell subsets exhibiting altered migratory and suppressive properties. Dysregulation of CYTH4 was associated with tumor initiation and progression, highlighting its contribution to immune cell trafficking and functional reprogramming within the tumor microenvironment (TME). CYTH4 (Cytohesin-4) was identified as a novel oncogenic factor in ccRCC, with expression upregulated in tumor, lymph node metastasis, and the aggressive ccB subtype. In vitro, overexpression of CYTH4 in 786-O cells enhanced colony formation and produced more aggressive xenografts in NOD/SCID mice. Mechanistically, CYTH4 physically interacted with PPP1R9B to induce pRb hyperphosphorylation. RNA-seq of CYTH4 xenografts showed enrichment of MYC Targets and E2F Targets alongside upregulation of the Sig27 metagene, with three Sig27 component genes confirmed as CYTH4- associated differentially expressed genes (DEGs). A derived 13-gene panel SigCYTH4NW robustly stratified poor overall survival across four ccRCC cohorts and 21 cancer types with stable hazard ratios strongly correlated with an immune checkpoint panel (SigIC), and showed predominant expression in tumor-associated macrophages (TAMs), exhausted CD8+ T cells, and Tregs in single-cell datasets. We validated a prostate cancer-derived and IQGAP1 associated novel 27-gene prognostic signature (Sig27) that robustly predicts poor prognosis in RCC. Sig27 presented a strong association with immunosuppressive features of the TME, including myeloid infiltration and immune inhibitory signaling. To further explore the clinical relevance of this, we constructed SigRZ, a 2-gene signature for predicting overall survival and disease progression in advanced RCC patients treated with the PD-1 inhibitor nivolumab. SigRZ effectively stratified patients by clinical outcome, underscoring the relevance of immune-associated transcriptional programs in determining immunotherapy response. Collectively, we identified two factors as promoters of tumor aggressiveness and tumor microenvironment changes. The development or validation of Sig27 and SigRZ demonstrates the translational potential of integrating tumor-intrinsic and immuneassociated molecular programs into clinically actionable biomarkers. Taken together, the findings advance our understanding of immune-driven tumor progression and provide a conceptual framework for biomarker development for RCC progression.","abstract_has_math":false,"creators":["Dong,Ying"],"institution":null,"degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":"Medical Sciences","school":null,"contributors":[],"advisors":["Tang, damu"],"committee_chairs":[],"committee_members":[],"year":2026,"date_issued":"2026","date_published":"2026","updated_at":"2026-11-18T19:36:16Z","subjects":[],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://doi.org/10.71548/25362"],"render_values":[{"text":"https://doi.org/10.71548/25362","href":"https://doi.org/10.71548/25362","code":true}]}],"person_identifier_entries":[]},"links":{"outbound_url":"https://hdl.handle.net/11375/33591","outbound_label":"Handle","outbound_source":"dc:identifier.uri","record_url":"https://hdl.handle.net/11375/33591","record_label":"Repository record","record_kind":"handle","record_source":"dc:identifier.uri","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://macsphere.mcmaster.ca/server/oai/request?verb=GetRecord&metadataPrefix=dim&identifier=oai%3Amacsphere.mcmaster.ca%3A11375%2F33591","prefix":"dim"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor.advisor","label":"Advisor","values":["Tang, damu"]},{"key":"dc:contributor.department","label":"Department","values":["Medical Sciences"]},{"key":"dc:creator","label":"Author","values":["Dong,Ying"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2026-09-23T17:45:04Z"]},{"key":"dc:date.issued","label":"Date","values":["2026"]},{"key":"dc:type","label":"Dc Type","values":["Thesis"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["https://hdl.handle.net/11375/33591","https://doi.org/10.71548/25362"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Renal cell carcinoma (RCC) is the predominant cause of kidney cancer death, owing to the disease’s aggressiveness-associated poor prognosis as well as challenges in early diagnosis and in predicting RCC evolution path, particularly in response to therapy. Currently, RCC cases are diagnosed incidentally through imaging; the disease prognosis is evaluated based on tumors’ histological features; and immune checkpoint inhibitor (ICI) is promising in treating patients with advanced RCC by taking advantage of enriched infiltration of CD8+ T cells without reliable criteria (biomarkers) for optimizing ICI therapy. My research focuses on advancing the current understanding of RCC particularly factors relevant to RCC’s immune escape and identifying novel and effective biomarkers to improve patient management. Specifically, we investigated novel factors: Contactin 1 (CNTN1) and CYTH4 for their contributions to RCC progression, and multigene panels, Sig27 and SigRZ, as novel predictive biomarkers of RCC. Notably, CNTN1, CYTH4, and Sig27 display intrinsic connections with the immunosuppressive microenvironment of RCC. Contactin 1 (CNTN1) is a cell adhesion protein and has been reported to be associated with tumor invasion, metastasis, and poor prognosis across multiple cancer types. In this study, we demonstrate that CNTN1 expression is strongly associated with tumor aggressiveness and adverse clinical outcomes in RCC. Tumors with high expression of CNTN1 show upregulation of genes and pathways involved in cell proliferation, migration, and extracellular matrix remodeling, consistent with a highly invasive tumor state, and elevated CNTN1 expression correlates with enrichment of immunosuppressive signaling pathways and immune cell populations. In vitro, CNTN1 promotes tumor cell migration and invasion. In vivo, CNTN1-overexpressing Renca (Renca-CNTN1) allograft exhibits a biphasic growth, an early growth suppression followed by later acceleration compared to Renca-EV (empty vector) allografts. Surgical resection of early tumors (100 mm3) showed CNTN1 tumors recur at lower rates (3/10=30%) than EV allografts (10/10=100%), indicating that Renca-CNTN1 allografts initiate anti-tumor immunity which suppresses early tumor growth and their subsequent recurrence following surgical resection. Tumor cells isolated from recurrent Renca-CNTN1 tumors produced aggressive allografts in BALB/c mice compared to tumor cells isolated from Renca-EV recurrent tumors. Renca-CNTN1 tumors that escape this immunosurveillance window develop interferon-dominated transcriptional programs with co-expression of the exhaustion markers TOX, PD-1, and LAG-3, alongside CD8+ T cell infiltration with impaired cytolytic function. CNTN1 thus drives a stage-dependent immune evasion program in RCC, coupled with enhancing proliferation and the relevant pathways. CYTH4 (Cytohesin 4), a regulator of ARF-mediated signaling and cytoskeletal dynamics, was selectively enriched in immune cell subsets exhibiting altered migratory and suppressive properties. Dysregulation of CYTH4 was associated with tumor initiation and progression, highlighting its contribution to immune cell trafficking and functional reprogramming within the tumor microenvironment (TME). CYTH4 (Cytohesin-4) was identified as a novel oncogenic factor in ccRCC, with expression upregulated in tumor, lymph node metastasis, and the aggressive ccB subtype. In vitro, overexpression of CYTH4 in 786-O cells enhanced colony formation and produced more aggressive xenografts in NOD/SCID mice. Mechanistically, CYTH4 physically interacted with PPP1R9B to induce pRb hyperphosphorylation. RNA-seq of CYTH4 xenografts showed enrichment of MYC Targets and E2F Targets alongside upregulation of the Sig27 metagene, with three Sig27 component genes confirmed as CYTH4- associated differentially expressed genes (DEGs). A derived 13-gene panel SigCYTH4NW robustly stratified poor overall survival across four ccRCC cohorts and 21 cancer types with stable hazard ratios strongly correlated with an immune checkpoint panel (SigIC), and showed predominant expression in tumor-associated macrophages (TAMs), exhausted CD8+ T cells, and Tregs in single-cell datasets. We validated a prostate cancer-derived and IQGAP1 associated novel 27-gene prognostic signature (Sig27) that robustly predicts poor prognosis in RCC. Sig27 presented a strong association with immunosuppressive features of the TME, including myeloid infiltration and immune inhibitory signaling. To further explore the clinical relevance of this, we constructed SigRZ, a 2-gene signature for predicting overall survival and disease progression in advanced RCC patients treated with the PD-1 inhibitor nivolumab. SigRZ effectively stratified patients by clinical outcome, underscoring the relevance of immune-associated transcriptional programs in determining immunotherapy response. Collectively, we identified two factors as promoters of tumor aggressiveness and tumor microenvironment changes. The development or validation of Sig27 and SigRZ demonstrates the translational potential of integrating tumor-intrinsic and immuneassociated molecular programs into clinically actionable biomarkers. Taken together, the findings advance our understanding of immune-driven tumor progression and provide a conceptual framework for biomarker development for RCC progression."]},{"key":"dc:description.degree","label":"Dc Description Degree","values":["Doctor of Philosophy (PhD)"]},{"key":"dc:title","label":"Title","values":["Identification and Characterization of Novel Oncogenic Factors and Predictive Biomarkers of Clear Cell Renal Cell Carcinoma"]},{"key":"others:access_status","label":"Others Access Status","values":["embargo"]}]}],"canonical_facts":{"dc:contributor.advisor":["Tang, damu"],"dc:contributor.department":["Medical Sciences"],"dc:creator":["Dong,Ying"],"dc:date.accessioned":["2026-09-23T17:45:04Z"],"dc:date.issued":["2026"],"dc:description.abstract":["Renal cell carcinoma (RCC) is the predominant cause of kidney cancer death, owing to the disease’s aggressiveness-associated poor prognosis as well as challenges in early diagnosis and in predicting RCC evolution path, particularly in response to therapy. Currently, RCC cases are diagnosed incidentally through imaging; the disease prognosis is evaluated based on tumors’ histological features; and immune checkpoint inhibitor (ICI) is promising in treating patients with advanced RCC by taking advantage of enriched infiltration of CD8+ T cells without reliable criteria (biomarkers) for optimizing ICI therapy. My research focuses on advancing the current understanding of RCC particularly factors relevant to RCC’s immune escape and identifying novel and effective biomarkers to improve patient management. Specifically, we investigated novel factors: Contactin 1 (CNTN1) and CYTH4 for their contributions to RCC progression, and multigene panels, Sig27 and SigRZ, as novel predictive biomarkers of RCC. Notably, CNTN1, CYTH4, and Sig27 display intrinsic connections with the immunosuppressive microenvironment of RCC. Contactin 1 (CNTN1) is a cell adhesion protein and has been reported to be associated with tumor invasion, metastasis, and poor prognosis across multiple cancer types. In this study, we demonstrate that CNTN1 expression is strongly associated with tumor aggressiveness and adverse clinical outcomes in RCC. Tumors with high expression of CNTN1 show upregulation of genes and pathways involved in cell proliferation, migration, and extracellular matrix remodeling, consistent with a highly invasive tumor state, and elevated CNTN1 expression correlates with enrichment of immunosuppressive signaling pathways and immune cell populations. In vitro, CNTN1 promotes tumor cell migration and invasion. In vivo, CNTN1-overexpressing Renca (Renca-CNTN1) allograft exhibits a biphasic growth, an early growth suppression followed by later acceleration compared to Renca-EV (empty vector) allografts. Surgical resection of early tumors (100 mm3) showed CNTN1 tumors recur at lower rates (3/10=30%) than EV allografts (10/10=100%), indicating that Renca-CNTN1 allografts initiate anti-tumor immunity which suppresses early tumor growth and their subsequent recurrence following surgical resection. Tumor cells isolated from recurrent Renca-CNTN1 tumors produced aggressive allografts in BALB/c mice compared to tumor cells isolated from Renca-EV recurrent tumors. Renca-CNTN1 tumors that escape this immunosurveillance window develop interferon-dominated transcriptional programs with co-expression of the exhaustion markers TOX, PD-1, and LAG-3, alongside CD8+ T cell infiltration with impaired cytolytic function. CNTN1 thus drives a stage-dependent immune evasion program in RCC, coupled with enhancing proliferation and the relevant pathways. CYTH4 (Cytohesin 4), a regulator of ARF-mediated signaling and cytoskeletal dynamics, was selectively enriched in immune cell subsets exhibiting altered migratory and suppressive properties. Dysregulation of CYTH4 was associated with tumor initiation and progression, highlighting its contribution to immune cell trafficking and functional reprogramming within the tumor microenvironment (TME). CYTH4 (Cytohesin-4) was identified as a novel oncogenic factor in ccRCC, with expression upregulated in tumor, lymph node metastasis, and the aggressive ccB subtype. In vitro, overexpression of CYTH4 in 786-O cells enhanced colony formation and produced more aggressive xenografts in NOD/SCID mice. Mechanistically, CYTH4 physically interacted with PPP1R9B to induce pRb hyperphosphorylation. RNA-seq of CYTH4 xenografts showed enrichment of MYC Targets and E2F Targets alongside upregulation of the Sig27 metagene, with three Sig27 component genes confirmed as CYTH4- associated differentially expressed genes (DEGs). A derived 13-gene panel SigCYTH4NW robustly stratified poor overall survival across four ccRCC cohorts and 21 cancer types with stable hazard ratios strongly correlated with an immune checkpoint panel (SigIC), and showed predominant expression in tumor-associated macrophages (TAMs), exhausted CD8+ T cells, and Tregs in single-cell datasets. We validated a prostate cancer-derived and IQGAP1 associated novel 27-gene prognostic signature (Sig27) that robustly predicts poor prognosis in RCC. Sig27 presented a strong association with immunosuppressive features of the TME, including myeloid infiltration and immune inhibitory signaling. To further explore the clinical relevance of this, we constructed SigRZ, a 2-gene signature for predicting overall survival and disease progression in advanced RCC patients treated with the PD-1 inhibitor nivolumab. SigRZ effectively stratified patients by clinical outcome, underscoring the relevance of immune-associated transcriptional programs in determining immunotherapy response. Collectively, we identified two factors as promoters of tumor aggressiveness and tumor microenvironment changes. The development or validation of Sig27 and SigRZ demonstrates the translational potential of integrating tumor-intrinsic and immuneassociated molecular programs into clinically actionable biomarkers. Taken together, the findings advance our understanding of immune-driven tumor progression and provide a conceptual framework for biomarker development for RCC progression."],"dc:description.degree":["Doctor of Philosophy (PhD)"],"dc:identifier.uri":["https://hdl.handle.net/11375/33591","https://doi.org/10.71548/25362"],"dc:title":["Identification and Characterization of Novel Oncogenic Factors and Predictive Biomarkers of Clear Cell Renal Cell Carcinoma"],"dc:type":["Thesis"],"others:access_status":["embargo"]},"updated_at":"2026-11-18T19:36:16Z"}